Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

622 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes.
Roufosse FE, Kahn JE, Gleich GJ, Schwartz LB, Singh AD, Rosenwasser LJ, Denburg JA, Ring J, Rothenberg ME, Sheikh J, Haig AE, Mallett SA, Templeton DN, Ortega HG, Klion AD. Roufosse FE, et al. Among authors: gleich gj. J Allergy Clin Immunol. 2013 Feb;131(2):461-7.e1-5. doi: 10.1016/j.jaci.2012.07.055. Epub 2012 Oct 4. J Allergy Clin Immunol. 2013. PMID: 23040887 Free PMC article. Clinical Trial.
Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.
Steinfeld J, Bradford ES, Brown J, Mallett S, Yancey SW, Akuthota P, Cid MC, Gleich GJ, Jayne D, Khoury P, Langford CA, Merkel PA, Moosig F, Specks U, Weller PF, Wechsler ME. Steinfeld J, et al. Among authors: gleich gj. J Allergy Clin Immunol. 2019 Jun;143(6):2170-2177. doi: 10.1016/j.jaci.2018.11.041. Epub 2018 Dec 19. J Allergy Clin Immunol. 2019. PMID: 30578883 Free PMC article. Clinical Trial.
Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial.
Roufosse F, Kahn JE, Rothenberg ME, Wardlaw AJ, Klion AD, Kirby SY, Gilson MJ, Bentley JH, Bradford ES, Yancey SW, Steinfeld J, Gleich GJ; HES Mepolizumab study group. Roufosse F, et al. Among authors: gleich gj. J Allergy Clin Immunol. 2020 Dec;146(6):1397-1405. doi: 10.1016/j.jaci.2020.08.037. Epub 2020 Sep 18. J Allergy Clin Immunol. 2020. PMID: 32956756 Free PMC article. Clinical Trial.
Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5.
Rothenberg ME, Roufosse F, Faguer S, Gleich GJ, Steinfeld J, Yancey SW, Mavropoulou E, Kwon N; HES Mepolizumab Study Group. Rothenberg ME, et al. Among authors: gleich gj. J Allergy Clin Immunol Pract. 2022 Sep;10(9):2367-2374.e3. doi: 10.1016/j.jaip.2022.04.037. Epub 2022 May 12. J Allergy Clin Immunol Pract. 2022. PMID: 35568330 Free article. Clinical Trial.
Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.
Ogbogu PU, Bochner BS, Butterfield JH, Gleich GJ, Huss-Marp J, Kahn JE, Leiferman KM, Nutman TB, Pfab F, Ring J, Rothenberg ME, Roufosse F, Sajous MH, Sheikh J, Simon D, Simon HU, Stein ML, Wardlaw A, Weller PF, Klion AD. Ogbogu PU, et al. Among authors: gleich gj. J Allergy Clin Immunol. 2009 Dec;124(6):1319-25.e3. doi: 10.1016/j.jaci.2009.09.022. J Allergy Clin Immunol. 2009. PMID: 19910029 Free PMC article.
Refining the definition of hypereosinophilic syndrome.
Simon HU, Rothenberg ME, Bochner BS, Weller PF, Wardlaw AJ, Wechsler ME, Rosenwasser LJ, Roufosse F, Gleich GJ, Klion AD. Simon HU, et al. Among authors: gleich gj. J Allergy Clin Immunol. 2010 Jul;126(1):45-9. doi: 10.1016/j.jaci.2010.03.042. J Allergy Clin Immunol. 2010. PMID: 20639008 Free PMC article. Review.
622 results